iVigee » AI in Pharmacovigilance » AI in Signal Detection

AI in Signal Detection

Signal detection is the process of identifying early, unconfirmed evidence that a medicine may cause new or previously unrecognised adverse events. It combines quantitative screening - disproportionality analysis across databases like FAERS, EudraVigilance and VigiBase - with qualitative clinical review. AI changes the economics of both: agents scan continuously and surface evidence a single reviewer would never find, while validation of every signal stays with a qualified human.

Explore this Service

Ask a PV expert

Every market. Every authority. Local expertise on the ground.

AI in Pharmacovigilance

Where AI genuinely helps

Quality rises because decisions are challenged, not rubber-stamped. AI agents surface evidence and perspectives that a single reviewer would never have found, expose blind spots before they become errors, and ensure no individual assessor's judgement is the only one shaping the outcome.

In signal work that means:

Continuous screening instead of periodic runs - signals surface when the data moves, not when the calendar says so.
Multi-source coverage: spontaneous reports, literature, real-world data.
Consistent disproportionality methods with documented thresholds.
Prioritisation support: severity, novelty and public-health impact made explicit.

Where it fails and why a human signals every outcome

Statistics cannot prove causality. A disproportionality score is a hypothesis, not a conclusion - and a model cannot weigh comorbidities, disease progression or off-label use the way a clinician does. That is why signal validation outcomes sit in the "in the loop" oversight mode: the agent assembles the evidence package with its uncertainty made explicit, and a qualified human authorises. The agent cannot proceed without that signature.

AI in Pharmacovigilance

The Signal Management Lifecycle

Agent-supported end to end

Detection

Continuous quantitative and qualitative screening across all data sources.

Analysis & prioritisation

Signals ranked by severity, strength of evidence and public-health impact.

Validation

Evidence sufficiency checked, documentation assembled - human authorises the outcome.

Assessment & action

Causality evaluation and risk-minimisation recommendations, with the full audit trail behind every step.

FAQ

The process of identifying early, unconfirmed evidence of a possible causal relationship between a medicine and a new or changed risk, using statistical screening and clinical review.

A signal is a hypothesis supported by preliminary evidence; it becomes an identified or potential risk only after assessment confirms the strength of the causal association.

A statistical method that flags drug–event pairs reported more frequently than expected by chance in databases such as FAERS or VigiBase — the starting point of quantitative signal detection, never its conclusion.

AI widens coverage and consistency - continuous screening, more sources, explicit uncertainty. But it complements clinical judgement rather than replacing it: validation outcomes always carry a human signature.

A defined signal management process - detection, validation, analysis and prioritisation, assessment, and action — with documented methodology and traceability. The agentic model maps to it step by step.

Explore AI in Pharmacovigilance

Explore all AI services

LET'S TALK

Put Your Question to a Pharmacovigilance Expert

Tell us what you're working on, whatever the stage or market. We'll make sure your question reaches the specialist who leads that area, and that you get a real, considered answer back, not a brochure.

Actual iVigeeans ↑

Does It Really Matter if My PV Vendor Is Physician-Led?

Before you compare vendors or talk about outsourcing, you need to understand what great pharmacovigilance leadership really looks like. Dr. Henry Seto answers the question directly, and honestly. Press play to hear what most vendors won't tell you. ↓

More pharmacovigilance insights from people who live it.

From physician-led videos to practical guides and regulatory updates, everything in our Knowledge Hub is designed to help you make confident, informed decisions.

Start learning